Department of Emergency and Critical Care Medicine, Second Affiliated Hospital of Nanchang University , Nanchang , Jiangxi , P.R. China.
Department of the Graduate School, Nanchang University , Nanchang , Jiangxi , People's Republic of China.
Cancer Biol Ther. 2019;20(11):1380-1388. doi: 10.1080/15384047.2019.1647056. Epub 2019 Aug 6.
The prognostic value of Chemokine (C-X-C motif) ligand 1 (CXCL1) in various types of cancer remains controversial. Here we aimed to evaluate the prognostic role of CXCL1 for cancer. A comprehensively search of the PubMed, Embase, Web of Science, Wanfang and China National Knowledge Internet databases was conducted to retrieve eligible studies meeting the inclusion criteria. Overall survival (OS), progression-free survival (PFS) and various clinicopathological parameters were defined as endpoints. Stata SE12.0 software was used for quantitative meta-analysis. A total of 17 studies encompassing 2265 cancer patients were included. Our meta-analysis showed that patients with higher CXCL1 expression had significantly shorter OS, according to both multivariate (HR 1.51, 95% CI 1.19-1.83, P < .01) and univariate analysis (HR 2.08, 95% CI 1.62-2.54, P < .01). Furthermore, higher CXCL1 expression was significantly correlated with advanced TNM stage and lymph node metastasis (both P < .05). High CXCL1 expression is a risk factor for cancer prognosis indicating a poor OS, and advanced TNM stage and lymph node metastasis, demonstrating that it may be a promising prognostic biomarker for different cancers.
趋化因子（C-X-C 基序）配体 1（CXCL1）在各种类型癌症中的预后价值仍存在争议。在这里，我们旨在评估 CXCL1 对癌症的预后作用。通过全面检索 PubMed、Embase、Web of Science、万方和中国国家知识互联网数据库，检索符合纳入标准的合格研究。总生存期（OS）、无进展生存期（PFS）和各种临床病理参数被定义为终点。使用 Stata SE12.0 软件进行定量荟萃分析。共有 17 项研究纳入了 2265 名癌症患者。我们的荟萃分析表明，根据多变量（HR 1.51，95%CI 1.19-1.83，P<.01）和单变量分析（HR 2.08，95%CI 1.62-2.54，P<.01），CXCL1 表达较高的患者 OS 明显更短。此外，CXCL1 表达较高与较晚的 TNM 分期和淋巴结转移显著相关（均 P<.05）。高 CXCL1 表达是癌症预后的危险因素，提示 OS 较差，且与较晚的 TNM 分期和淋巴结转移相关，表明其可能是不同癌症有前途的预后生物标志物。
